|
1
|
Munker R and Calin GA: MicroRNA profiling
in cancer. Clin Sci (Lond). 121:141–158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Da Sacco L and Masotti A: Recent insights
and novel bioinformatics tools to understand the role of microRNAs
binding to 5′untranslated region. Int J Mol Sci. 14:480–495. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meltzer PS: Cancer genomics: Small RNAs
with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaur A, Jewell DA, Liang Y, Ridzon D,
Moore JH, Chen C, Ambros VR and Israel MA: Characterization of
microRNA expression levels and their biological correlates in human
cancer cell lines. Cancer Res. 67:2456–2468. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:pp. 2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro- RNA genes miR15
and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 99:pp. 15524–15529. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang TC, Wentzel EA, Kent OA, et al:
Transactivation of miR-34a by p53 broadly influences gene
expression and promotes apoptosis. Mol Cell. 26:745–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mendell JT: miRiad roles for the miR-17-92
cluster in development and disease. Cell. 133:217–222. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galasso M, Sandhu SK and Volinia S:
MicroRNA expression signatures in solid malignancies. Cancer J.
18:238–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sassen S, Miska EA and Caldas C: MicroRNA:
Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Negrini M and Calin GA: Breast cancer
metastasis: A microRNA story. Breast Cancer Res. 10:2032008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Valastyan S: Roles of microRNAs and other
non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol
Neoplasia. 17:23–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marino AL, Evangelista AF, Macedo T,
Silveira HC, Kerr LM, Vieira RA, Longatto AF and Silveira MM:
Differential expression profile of microRNAs associated with human
breast cancer progression. BMC Proc. 7 Suppl 2:pp. P92013;
View Article : Google Scholar
|
|
18
|
Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X
and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via
downregulation of the expression of Ezrin in F5M2 cells. Int J Mol
Med. 30:1013–1020. 2012.PubMed/NCBI
|
|
19
|
Wang J, Wang X, Li Z, Liu H and Teng Y:
MicroRNA-183 suppresses retinoblastoma cell growth, invasion and
migration by targeting LRP6. FEBS J. 281:1355–1365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He W, Li Y, Chen X, Lu L, Tang B, Wang Z,
Pan Y, Cai S, He Y and Ke Z: miR-494 acts as an anti-oncogene in
gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol.
29:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Silva-Oliveira RJ, Silva VA, Martinho O,
Cruvinel-Carloni A, Melendez ME, Rosa MN, De Paula FE, de Souza
Viana L, Carvalho AL and Reis RM: Cytotoxicity of allitinib, an
irreversible anti-EGFR agent, in a large panel of human
cancer-derived cell lines: KRAS mutation status as a predictive
biomarker. Cell Oncol (Dordr). 39:253–263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kammermann M, Denelavas A, Imbach A,
Grether U, Dehmlow H, Apfel CM and Hertel C: Impedance measurement:
A new method to detect ligand-biased receptor signaling. Biochem
Biophys Res Commun. 412:419–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maere S, Heymans K and Kuiper M: BiNGO: A
Cytoscape plugin to assess overrepresentation of gene ontology
categories in biological networks. Bioinformatics. 21:3448–3449.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Girish V and Vijayalakshmi A: Affordable
image analysis using NIH Image/ImageJ. Indian J Cancer.
41:472004.PubMed/NCBI
|
|
27
|
Subik K, Lee JF, Baxter L, Strzepek T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER PR, HER2, CK5/6, EGFR, Ki-67
and AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
28
|
Haga CL and Phinney DG: MicroRNAs in the
imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal
transition by targeting the TWIST1 protein signaling network. J
Biol Chem. 287:42695–42707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lowery AJ, Miller N, Dwyer RM and Kerin
MJ: Dysregulated miR-183 inhibits migration in breast cancer cells.
BMC Cancer. 10:5022010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Limame R, Wouters A, Pauwels B, Fransen E,
Peeters M, Lardon F, De Wever O and Pauwels P: Comparative analysis
of dynamic cell viability, migration and invasion assessments by
novel real-time technology and classic endpoint assays. PLoS One.
7:e465362012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ohdaira H, Sekiguchi M, Miyata K and
Yoshida K: MicroRNA-494 suppresses cell proliferation and induces
senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holliday DL and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lacroix M and Leclercq G: Relevance of
breast cancer cell lines as models for breast tumours: An update.
Breast Cancer Res Treat. 83:249–289. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mizuarai S, Machida T, Kobayashi T,
Komatani H, Itadani H and Kotani H: Expression ratio of CCND1 to
CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and
clinical tumor samples. Mol Cancer. 10:312011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chinnam M and Goodrich DW: RB1,
development, and cancer. Curr Top Dev Biol. 94:129–169. 2011.
View Article : Google Scholar : PubMed/NCBI
|
